Paromomycin loaded solid lipid nanoparticles: Characterization of production parameters

Ghadiri, Maryam Khaleghi; Vatanara, Alireza; Doroud, Delaram; Najafabadi, Abdolhossein R.

doi:10.1007/s12257-010-0331-5

Cited by 30 publications

(23 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A modified high shear homogenization (HSH) microemulsion technique was used to prepare PM-SLN as previously described (30,32). Briefly, lipid (stearic acid) was heated to 85°C.…”

Section: Preparation Of Pm-slnmentioning

confidence: 99%

“…The properties of each PM-SLN formulation such as size, polydispersity index, % paromomycin loading, zeta potential, and entrapment efficiency were determined. The particle diameter of each sample was measured in triplicate by dynamic light scattering (Malvern, Nano-ZS, UK) as previously described (30,32).…”

Section: Preparation Of Pm-slnmentioning

confidence: 99%

“…Their effects on average diameter, size distribution, and entrapment efficiency of the lipid nanoparticles for maximized entrapment efficiency, size particle reduction, and distribution were determined (32). Three quantitative factors-paromomycin content, weight fraction of Tween 80, and drug-to-lipid ratio-were also investigated at two levels for SLN formulation in a fractional factorial design (32). Briefly, the obtained results indicated that microemulsion was the most efficient method and stearic acid was the preferred lipid for SLN formulation (32).…”

Section: Pm-sln Formulationmentioning

confidence: 99%

See 2 more Smart Citations

Drug Targeting to Macrophages With Solid Lipid Nanoparticles Harboring Paromomycin: an In Vitro Evaluation Against L. major and L. tropica

et al. 2015

Self Cite

View full text Add to dashboard Cite

Abstract. Leishmaniasis is a worldwide disease that leads to high mortality and morbidity in human populations. Today, leishmaniasis is managed via drug therapy. The drugs that are already in clinical use are limited to a number of toxic chemical compounds and their parasite drug resistance is increasing. It is therefore essential, in order to circumvent the current difficulties, to design a new anti-leishmanial drug treatment strategy. Besides producing new, active anti-leishmanial entities, another promising strategy could be developing novel delivery systems and formulations of the existing pharmaceutical ingredients to improve drug efficacy. In the present study, paromomycin sulfate (PM), as one of the promising antileishmanial drugs, was formulated in solid lipid nanoparticles (SLN), and its in vitro efficacy was investigated against different strains of Leishmania using a MTT test, Parasite-Rescue-Transformation-Assay, SYTO Green staining, and fluorescent microscope imaging. The results show that PM-loaded SLN is significantly more effective than PM in inhibiting parasite propagation (P<0.05) and that cytotoxicity of PM-SLN formulations is size dependent. According to our results, delivery of the drugs to the macrophages via nanoparticle utilization seems to be an accessible and practical approach.KEY WORDS: cutaneous leishmaniasis; drug delivery system; paromomycin sulfate; solid lipid nanoparticle.

show abstract

“…A modified high shear homogenization (HSH) microemulsion technique was used to prepare PM-SLN as previously described (30,32). Briefly, lipid (stearic acid) was heated to 85°C.…”

Section: Preparation Of Pm-slnmentioning

confidence: 99%

Section: Preparation Of Pm-slnmentioning

confidence: 99%

Section: Pm-sln Formulationmentioning

confidence: 99%

See 1 more Smart Citation

Drug Targeting to Macrophages With Solid Lipid Nanoparticles Harboring Paromomycin: an In Vitro Evaluation Against L. major and L. tropica

et al. 2015

Self Cite

View full text Add to dashboard Cite

show abstract

“…14,15 Several methods are employed in the SLNs preparation, however the method of emulsification-solvent evaporation is usually applied when the bioactive compound has low solubility in the lipid or it is thermosensitive. 16,17 The common lipids used to obtain the SLNs are triglycerides, 12 fatty acids 13 and waxes. 14 Among the triglycerides, emphasis is placed on trilaurin, tricaprin and tricaprylin, which were selected to form the lipid matrix of the nanosystems synthesized in this work.…”

Section: Introductionmentioning

confidence: 99%

“…The SLNs are colloidal dispersions containing a surfactant agent and a matrix composed of solid lipids at room and corporal temperature. 12,13 SLNs present some advantages in comparison to conventional carrier systems such as low toxicity, efficient incorporation of hydrophobic bioactive compounds in their lipid core, the ability to influence the release profile of their cargo from the solid matrix and easy large-scale production. 14,15 Several methods are employed in the SLNs preparation, however the method of emulsification-solvent evaporation is usually applied when the bioactive compound has low solubility in the lipid or it is thermosensitive.…”

mentioning

confidence: 99%

Preliminary Evaluation of Novel Triglyceride-Based Nanocomposites for Biomedical Applications

Almeida¹,

Gallo²,

Silva³

et al. 2017

J. Braz. Chem. Soc.

View full text Add to dashboard Cite

This work describes the development and characterization of triglyceride-based magnetic nanocomposites for application in magnetic hyperthermia and controlled drug delivery. The magnetic solid lipid nanocomposites (MSLN) constituted by mixtures of trilaurin-tricaprylin and trilaurin-tricaprin have been successfully obtained by emulsification-solvent evaporation method. The developed MSLNs were subjected to an external oscillating magnetic field and showed significant hyperthermia. The samples were exposed to frequencies of 688 and 869 kHz causing, respectively, a temperature increase of 15.5 and 22.7 °C (trilaurin-tricaprylin) and 17.3 and 26.1 °C (trilaurin-tricaprin). Also, in vitro assays in the absence of magnetic field showed that the triglyceride-based formulations were able first to encapsulate and then to sustained release an antitumoural hydrophobic drug. After 72 h of assay trilaurin-tricaprylin and trilaurin-tricaprin released 73 and 55% of their cargo, respectively. In addition, MSLN exhibited low in vitro cytotoxic activity against human neutrophils.Keywords: lipid mixture, magnetic hyperthermia, drug delivery, oncocalyxone-A IntroductionNanotechnology is an expanding sector and the use of superparamagnetic iron oxide nanoparticles (SPIONs) is attracting increasing attention in several areas. SPIONs are widely employed for biotechnological applications through the development of magnetic systems for use in: cell separation, as contrast agents for magnetic resonance imaging (MRI), magnetic hyperthermia, targeted bioactive compounds delivery and biosensors. [1][2][3][4] Such applications explore the biggest advantages of using SPIONs: biocompatibility and satisfactory magnetic response at applied magnetic field (superparamagnetic character). 5,6 The surface of the magnetic nanoparticles should be modified, not only in order to prevent oxidation and aggregation, but also to provide colloidal stability, reduced magnetic susceptibility, as well as to expand the effectiveness of cellular uptake and biodistribution. The hydroxyl groups present on the surface of nanoparticles can function as an anchor point for various types of compounds such as oleic acid, which is commonly used in the synthesis of magnetic ferrofluids. The criteria adopted to select the appropriate coating of magnetic nanoparticles depends mainly on the intended application. In the case of this research, magnetic nanoparticles made of iron oxide were coated with oleic acid (Fe 3 O 4 @OA) for subsequent incorporation into lipid carriers. 7-9The lipid carriers have been widely used as they also possess excellent characteristics such as biocompatibility Preliminary Evaluation of Novel Triglyceride-Based Nanocomposites for Biomedical Applications J. Braz. Chem. Soc. 1548 and versatility, and they have been proposed for the delivery of bioactive compounds by oral, intravenous, topical and parenteral routes. 10,11The solid lipid nanoparticles (SLNs) emerged in the early 90's and currently are alternative encapsulation systems and carriers o...

show abstract

Leishmaniasis

Imani¹,

Dehghan²

2020

Nanobiotechnology in Diagnosis, Drug Delivery, and Treatment

View full text Add to dashboard Cite

Paromomycin loaded solid lipid nanoparticles: Characterization of production parameters

Cited by 30 publications

References 18 publications

Drug Targeting to Macrophages With Solid Lipid Nanoparticles Harboring Paromomycin: an In Vitro Evaluation Against L. major and L. tropica

Drug Targeting to Macrophages With Solid Lipid Nanoparticles Harboring Paromomycin: an In Vitro Evaluation Against L. major and L. tropica

Preliminary Evaluation of Novel Triglyceride-Based Nanocomposites for Biomedical Applications

Leishmaniasis

Contact Info

Product

Resources

About